Reece Smith H, Memon A, Smart C J, Dewbury K
Br J Urol. 1986 Feb;58(1):36-40. doi: 10.1111/j.1464-410x.1986.tb05424.x.
A double-blind trial comparing the effect of Permixon (160 mg bd) against placebo in the treatment of benign prostatic hypertrophy is described. In both groups a significant improvement in flow rate and subjective assessment of symptoms was seen. There was no significant difference between the results of treatment in either group.
描述了一项双盲试验，比较了Permixon（每日两次，每次160毫克）与安慰剂治疗良性前列腺增生的效果。两组的流速和症状主观评估均有显著改善。两组治疗结果之间无显著差异。
